BACKGROUND: Infectious diseases remain a significant cause of morbidity and mortality. Cefpirome, a fourth generation Cephalosporin, is a potent antibiotic against a wide variety of organisms that may be used alone or in combination with other antimicrobials to combat various infections.

OBJECTIVE: This is a post-marketing surveillance study documenting the safety and efficacy of cefpirome among Filipino patients.

METHODOLOGY: This was a multicenter, open-label, noncomparative study involving 402 patients who received at least one dose of cefpirome. Safety and efficacy data were gathered.

RESULTS: Cefpirome was used as monotherapy in majority of the cases. Pneumonia (76%) was the most frequent indication for the use of this drug. The most commonly utilized dosage regimen was 2.0 grams every 12 hours for a mean of 4.2 days. This was associated with a successful clinical outcome in almost 90% of cases. There was almost negligible side effect reported.

CONCLUSION: The use of cefpirome was shown to be safe and well-tolerated with associated successful clinical outcomes among Filipino patients. 

Human ; Male ; Female ; Aged ; Middle Aged ; Adult ; Cefpirome ; Anti-bacterial Agents ; Anti-infective Agents ; Cephalosporins ; Communicable Diseases ; Pneumonia ; Morbidity